Session (CTI)

PURPOSE: Asian health systems are rapidly adapting reimbursement, health technology assessment (HTA), and evidence-generation policies to balance timely patient access, affordability, and uncertainty. Recent reforms in China, South Korea, and Taiwan illustrate different approaches to using real-world evidence (RWE) in reimbursement policy, strengthening RWE guidance and evidence standards for healthcare decision-making, and linking earlier access with parallel review, conditional listing, HTA, and health technology reassessment (HTR). This workshop will provide a practical, comparative overview of how RWE and lifecycle HTA approaches are being used across these three systems to support access to innovation while maintaining health system sustainability. DESCRIPTION: Dr. Wu will discuss the initiation, development, and application of RWE in China’s reimbursement policies, highlighting how evidence generation is being integrated into coverage and access decisions. Professor Suh will present South Korea’s evolving use of RWE in reimbursement and healthcare decision-making, focusing on evidence requirements, decision uncertainty, and HIRA’s 2026 RWE guidance. Professor Ou will share Taiwan’s lifecycle HTA approach to accelerating patient access while managing uncertainty, including parallel review, conditional listing, and the growing role of RWE in HTA/HTR across the drug life cycle. The session will be structured as three presentations (12 minutes each), followed by facilitated comparison and audience interaction. Live polling will be used to engage participants regarding which RWE and lifecycle HTA tools are most transferable across settings, what evidence gaps most limit accelerated access, and how RWE should be governed when reimbursement decisions are made under uncertainty. Moderated Q&A will draw out cross-country lessons for Europe and global stakeholders. The workshop will benefit HTA bodies, payers, policymakers, researchers, industry, and clinicians interested in sustainable access, lifecycle value assessment, and the policy use of RWE.